Aberdeen Group
MLYS icon

Aberdeen Group’s Mineralys Therapeutics MLYS Stock Holding History

Aberdeen Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Buy
+689,235
New +$18.9M 0.03% 466

Other funds holding MLYS

AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Aberdeen Group's MLYS Position: Q2 2026 in Review

Aberdeen Group opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 689,235 shares worth $18.6M. The stake represents 0.03% of the portfolio and ranks #466 among its holdings.

29 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Aberdeen Group held 689,235 shares of Mineralys Therapeutics worth $18.6M as of Q2 2026.
  • Mineralys Therapeutics was a new Aberdeen Group position in Q2 2026.
  • Mineralys Therapeutics made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #466 holding.
  • 29 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.